Clinuvel: Phase III Vitiligo study participation opportunity
There is a new opportunity to participate in a Phase 3 clinical trial investigating a potential new treatment for vitiligo.
An investigational therapy called afamelanotide is being evaluated as a treatment for vitiligo patients with darker skin types.
About Clinuvel
Clinuvel Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders.
The company has recently been exploring afamelanotide and its potential uses for treatment vitiligo in patients with darker skin, read their 2022 news update here.
You can also read more on previous Afamelanotide research here.
What would participants be doing?
Eligible participants will receive ultraviolet light therapy, either alone or in combination with afamelanotide during the course of up to 14 clinic visits over a 12 month period.
Who can participate in this research?
You may be eligible to participate if you:
- Have vitiligo on your face and body
- Have medium to dark skin type
- Are ages 12+
- Are able to attend up to 14 clinic visits over 12 months
How can I take part?
To register your interest and learn more email clinicaltrials@clinuvel.com
Please support our work! You've enjoyed 1 article this month and we hope you have found it useful. Our work is entirely funded by memberships and donations, so please consider joining our charity today and supporting our work.
Already a member? Log in
